SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	dress of Reporting	<u>N</u>	2. Date of Event Requiring Stater Month/Day/Yea	ment	3. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Flex Pharma, Inc.</u> [FLKS ]						
	(Last) (First) (Middle) C/O FLEX PHARMA, INC. 800 BOYLSTON STREET, 24TH FL				4. Relationship of Reporting Pers (Check all applicable) X Director Officer (give title		10% Owner Other (specify		5. If Amendment, Date of Original Filed (Month/Day/Year) 01/28/2015		
(Street) BOSTON MA 02199 (City) (State) (Zip)					below)	below)		pplicable Line) X Form filed I	t/Group Filing (Check by One Reporting Person by More than One Verson		
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)				4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned           (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securi Underlying Derivative Securi			4. Conversion or Exercia	se Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
		Date Exercisable	Expiration Date	Title		Amount or Number of Shares	Price of Derivative Security	Direct (D) e or Indirect (I) (Instr. 5)			
Stock Option	(right to buy)		(1)	04/08/2024		Common Stock	28,021	0.6	D		
Stock Option (right to buy)		(2)	10/14/2024		Common Stock	7,005	4.28	D			
Series A Preferred Stock		(3)	(4)		Common Stock	50,000	0.00 <sup>(5)</sup>	D			

Explanation of Responses:

1. Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "2014 Plan"). 25% of the total shares underlying this option vest on April 9, 2015 the remaining shares vest 1/48 per month over the next 36 months thereafter, subject to continued service to the Issuer through each vesting date.

2. Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "2014 Plan"). 25% of the total shares underlying this option vest on April 9, 2015 the remaining shares vest 1/48 per month over the next 36 months thereafter, subject to continued service to the Issuer through each vesting date.

3. N/A

4. The shares have no expiration date.

5. The shares will automatically convert on a 4.2825-for-1 basis into shares of the Issuer's Common Stock immediately upon the closing of a Qualified Public Offering (as defined in the Amended and Restated Certificate of Incorporation) as filed with the State of Delaware.

## Remarks:

This amendment is filed to correct the Form 3 filed on 1/28/2015 which had a typographical error in the footnote regarding the preferred conversion rate into common shares upon the closing of a Qualified Public Offering. The Form 3 filed on 1/28/2015 should be disregarded. A Form 3-A was been filed on 1/30/2015 to report the correct conversion rate.

<u>/s/ John McCabe, Attorney-in-</u> <u>Fact</u> 01/30/2015

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY Know all, by these presents, that the undersigned hereby constitutes and appoints each of Robert Hadfield and John McCabe, signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or holder of 10% of more of a registered class of securities of Flex Pharma, Inc. (the "Company"), Forms 3, 4 and 5 and any amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 28th day of January, 2015.

/s/Peter Barton-Hutt
(Signature)

Peter Barton-Hutt (Print Name)